Project Grant R01DA066955
Award Date 8/15/26
Completion Date 5/31/31
Dollars Obligated $682K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Institute on Drug Abuse awarded The Washington University $116,865 on August 3, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the role of locus coeruleus mu opioid receptors in fentanyl drug seeking. The research establishes the specific contribution of the locus coeruleus, a brain region dense with mu opioid receptors, in modulating fentanyl-seeking behavior. Preliminary data from the investigator demonstrates that conditional knockout of...
- The National Institute on Drug Abuse awarded The Washington University $165,915 under the Drug Use and Addiction Research Programs (CFDA 93.279) on August 1, 2026, to investigate the role of myelin and oligodendrocytes in fentanyl withdrawal-induced negative affect. The research will determine the impact of fentanyl on myelination in the anterior cingulate cortex and examine how myelin loss drives withdrawal-induced negative affect. The project is structured as a K99/R00 Pathway to...
- The National Institute on Drug Abuse awarded The Washington University $1,155,062 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to generate multiomics data characterizing cellular mechanisms underlying fentanyl-induced respiratory depression in opioid overdose decedents. The award funds single-nucleus RNA-seq and ATAC-seq (snRNAseq and snATACseq) paired multiomics analysis of brainstem respiratory control regions—the prebotzinger complex and ventral...
- The National Institute on Drug Abuse (NIDA) awarded a Cooperative Agreement of $733,457 to The Washington University on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds research investigating the long-term neurodevelopmental impact of maternal opioid exposure and opioid management strategies in rodent offspring. The project evaluates how in utero oxycodone exposure, maintenance therapy with methadone and buprenorphine, and withdrawal mitigation...
- The National Institute on Drug Abuse awarded Washington State University $604,683 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to dissect the role of thalamic withdrawal-encoding ensembles in opioid use disorder through basic neuroscience research. The recipient will employ viral trap technology and multilevel circuit-based approaches—including ex vivo electrophysiology, optogenetics, in vivo calcium imaging, and fiber photometry—to characterize the...
- The National Institute on Drug Abuse awarded the University of Washington $100,228 on November 10, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to characterize the role of endogenous nociceptin opioid release from the central amygdala in reward outcome encoding. The recipient will conduct research examining how nociceptin-containing neurons in the central amygdala engage distinct reward properties—including reward probability and size—and project to the lateral...
- The National Institute on Drug Abuse awarded the Regents of the University of Minnesota $673,724 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to study how opioid exposure modifies nucleus accumbens microcircuits and to develop strategies to reverse or prevent maladaptive opioid-evoked neural plasticity. The research focuses on low-threshold spiking interneurons (LTSIs) in the nucleus accumbens, which are gatekeepers of nucleus accumbens output and regulate...
- The National Institute on Drug Abuse awarded the University of Washington $139,812 on August 6, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct basic research on serotonin and dopamine dynamics during kappa opioid-mediated aversion. This Project Grant (F31DA065365) funds investigation of how stress-induced activation of the dynorphin-kappa opioid receptor system modulates serotonin and dopamine signaling in the brain, with implications for understanding...
- The National Institute on Drug Abuse awarded The Trustees of The University of Pennsylvania $708,040 on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct basic research on distinct amygdalar neural circuits involved in pain and opioid dependence. The award funds investigation of how chronic opioid exposure alters specific brain circuits that mediate pain and threat responses, using a mouse model of fentanyl dependence compatible with postoperative pain....
- The National Institute on Drug Abuse awarded Washington State University $420,750 on July 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the neurobiological substrates of cannabis-seeking behavior through preclinical research models. The funded research combines fiber photometry and wireless recording techniques to examine how dynamic neural activity and dopamine release in corticostriatal circuits—specifically the medial prefrontal cortex and nucleus...